Physician profile
Anthony Spedale
NPI 1699778662
$13,096.13
in general payments reported to CMS, 2019-2025
36 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,546 · 2020: $1,479 · 2021: $2,324 · 2022: $2,406 · 2023: $1,994 · 2024: $1,777 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,340.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,389.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,787.95 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $1,131.56 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,093.05 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,017.78 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $663.26 | 2019-2022 | |
| Abbvie INC. | $617.51 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $605.65 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $487.25 | 2021-2025 | |
| Pfizer INC. | $372.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.90 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.72 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $236.90 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $207.70 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Eisai INC. | $194.53 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $186.22 | 2022-2025 | Quviviq, Quviviq |
| Novocure INC. | $170.00 | 2023 | Optune |
| Nevro Corp. | $122.47 | 2022-2024 | Senza |
| Astellas Pharma US INC | $116.25 | 2019-2020 | |
| Janssen Biotech, INC. | $116.10 | 2025 | Tremfya |
| Kowa Pharmaceuticals America, INC. | $114.56 | 2020-2023 | Livalo, Seglentis |
| Tactile Systems Technology INC | $98.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $96.09 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $94.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $92.79 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $81.12 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.47 | 2020-2024 | Eliquis |
| Esperion Therapeutics, INC. | $67.05 | 2024-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $43.19 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $41.74 | 2019-2025 | Austedo Xr |
| Paratek Pharmaceuticals, INC. | $36.56 | 2022-2025 | Nuzyra, Xhance |
| Boston Scientific Corporation | $23.17 | 2025 | Watchman Access System |
| Tris Pharma INC | $22.11 | 2025 | Dyanavel Xr |
| Baxter Healthcare | $15.31 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Averitas Pharma INC. | $13.81 | 2024 | Qutenza |
| Genentech USA, INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Spedale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.